The potential benefit of encorafenib plus cetuximab with chemotherapy compared with standard of care in people with BRAF V600E-mutant metastatic colorectal cancer in the BREAKWATER study: a plain language summary Journal Article
| Authors: | Kopetz, S.; Yoshino, T.; Van Cutsem, E.; Eng, C.; Kim, T. W.; Wasan, H. S.; Desai, J.; Ciardiello, F.; Yaeger, R.; Maughan, T. S.; Beyzarov, E.; Zhang, X.; Ferrier, G.; Zhang, X.; Tabernero, J. |
| Article Title: | The potential benefit of encorafenib plus cetuximab with chemotherapy compared with standard of care in people with BRAF V600E-mutant metastatic colorectal cancer in the BREAKWATER study: a plain language summary |
| Abstract: | Plain Language Summary: What is this summary about? BRAF V600E-mutant metastatic colorectal cancer is difficult to treat as people often do not respond to standard of care treatment and their cancer gets worse. The BREAKWATER study looked at whether encorafenib plus cetuximab with mFOLFOX6 was a better treatment than standard of care to treat this disease. What were the results? More participants in the encorafenib plus cetuximab with mFOLFOX6 group had their tumor shrink after treatment than those in the standard of care group (61% versus 40%). Participants in the encorafenib plus cetuximab and mFOLFOX6 group might live longer after starting treatment than those in the standard of care group. The side effects reported were expected by researchers. What do the results mean? Encorafenib plus cetuximab and mFOLFOX6 is the new standard of care for this cancer. This is an abstract of the Plain Language Summary of Publication article. View the full Plain Language Summary PDF of this article to read the full-text. © 2025 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group. |
| Keywords: | adult; middle aged; major clinical study; overall survival; side effect; colorectal cancer; metastasis; epidermal growth factor receptor; cetuximab; health care quality; liver metastasis; drug combination; folinic acid; health care personnel; caregiver; tumor growth; language; oxaliplatin; b raf kinase; adverse drug reaction; metastatic colorectal cancer; drug comparison; human; male; female; article; encorafenib; ecog performance status; plain language summary |
| Journal Title: | Future Oncology |
| Volume: | 21 |
| Issue: | 13 |
| ISSN: | 1479-6694 |
| Publisher: | Future Medicine |
| Date Published: | 2025-01-01 |
| Start Page: | 1541 |
| End Page: | 1552 |
| Language: | English |
| DOI: | 10.1080/14796694.2025.2491290 |
| PUBMED: | 40391894 |
| PROVIDER: | scopus |
| DOI/URL: | |
| Notes: | Article -- Source: Scopus |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work